Vaccines

UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine

Thursday, April 2, 2020 - 5:15pm

Kawaokas lab will insert gene sequences from SARS-CoV-2, the novel coronavirus that causes the disease COVID-19, into M2SR so that the new vaccine will also induce immunity against the coronavirus.

Key Points: 
  • Kawaokas lab will insert gene sequences from SARS-CoV-2, the novel coronavirus that causes the disease COVID-19, into M2SR so that the new vaccine will also induce immunity against the coronavirus.
  • Bharat Biotech in Hyderabad, India will then begin production scale-up for safety and efficacy testing in humans.
  • Bharat Biotech has commercialized 16 vaccines, including a vaccine developed against the H1N1 flu that caused the 2009 pandemic.
  • Bharat Biotech will manufacture the vaccine, conduct clinical trials and prepare to produce the vaccine for global distribution.

Seed of hope: COVID-19 vaccine trials begin

Thursday, April 2, 2020 - 2:00pm

Once proves effective after three phases of clinical trials, the vaccine is expected to be available for the public in as little as six months' time.

Key Points: 
  • Once proves effective after three phases of clinical trials, the vaccine is expected to be available for the public in as little as six months' time.
  • Having previously traveled to Sierra Leone during the Ebola outbreak, she developed China's first homegrown vaccine for the virus, making China the third country to put an Ebola vaccine into clinical trials.
  • After two months of hard work, they developed the recombinant novel coronavirus vaccine, using the same technology as was used for the Ebola vaccine.
  • The COVID-19 vaccine is a seed of hope for humanity, and one which is showing positive signs.

Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

Tuesday, March 31, 2020 - 9:05pm

GAITHERSBURG, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement with Novavax, Inc. (NASDAQ:NVAX) whereby Emergent will provide molecule-to-market contract development and manufacturing (CDMO) services to produce Novavaxs NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant.

Key Points: 
  • GAITHERSBURG, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement with Novavax, Inc. (NASDAQ:NVAX) whereby Emergent will provide molecule-to-market contract development and manufacturing (CDMO) services to produce Novavaxs NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant.
  • Novavax recently announced that NanoFlu met all primary objectives in its Phase 3 clinical trial evaluating immunogenicity and safety in adults aged 65 and older.
  • Emergent is pleased to expand our collaboration with Novavax to include large-scale production of NanoFlu, their novel influenza vaccine, said Syed T. Husain, SVP and CDMO business unit head at Emergent BioSolutions.
  • Under the terms of the agreement, Emergent will provide drug substance manufacturing services, including technology transfer and process validation and performance qualification to pave the way for commercial manufacturing.

Datatrak to Provide Virtual Collaboration & EDC Platform for Free for COVID-19 Trials

Tuesday, March 31, 2020 - 5:14pm

As weve begun to work with some of our current partners on their initial COVID-19 trials, we realized that we have an opportunity to materially impact fighting this virus.

Key Points: 
  • As weve begun to work with some of our current partners on their initial COVID-19 trials, we realized that we have an opportunity to materially impact fighting this virus.
  • So, in response to the global outbreak of the COVID-19 pandemic, we want to ensure all researchers working to contribute to a vaccine or effective treatment have access to a platform that can facilitate virtual teams collaboration, management, and execution of their COVID-19 clinical trials, said Scott DeMell, VP Sales at Datatrak.
  • Datatrak International is a worldwide technology and services company delivering unified eClinical solutions and related services for the clinical trials industry.
  • Datatrak built its multi-component, comprehensive solution on a single, unified platform.

VBI Vaccines Announces Collaboration with the National Research Council of Canada to Develop Pan-Coronavirus Vaccine Candidate Targeting COVID-19, SARS, and MERS

Tuesday, March 31, 2020 - 1:00pm

VBI Vaccines Inc. (NASDAQ: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced a collaboration with the National Research Council of Canada (NRC), Canadas largest federal research and development organization, to develop a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).

Key Points: 
  • VBI Vaccines Inc. (NASDAQ: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced a collaboration with the National Research Council of Canada (NRC), Canadas largest federal research and development organization, to develop a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).
  • Under the terms of the agreement, the NRC and VBI will collaborate to evaluate and select the optimal vaccine candidate.
  • VBIs lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM) and a prophylactic CMV vaccine candidate.
  • VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Vaxart Provides Update on its Oral COVID-19 Vaccine Program

Tuesday, March 31, 2020 - 1:00pm

Each of the COVID-19 vaccine constructs is based on a different coronavirus antigen combination, and Vaxart expects to advance the best performing vaccine to manufacturing for clinical trials.

Key Points: 
  • Each of the COVID-19 vaccine constructs is based on a different coronavirus antigen combination, and Vaxart expects to advance the best performing vaccine to manufacturing for clinical trials.
  • Developing a vaccine to meet this current public health threat is very important to all of us at Vaxart, said Sean Tucker, Ph.D., chief scientific officer of Vaxart.
  • In January, Vaxart initiated a program to develop a COVID-19 vaccine based on its VAASTTM platform.
  • Vaxart is a clinical-stage biotechnology company primarily focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform.

GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act

Monday, March 30, 2020 - 2:00pm

GeoVax is using itsGV-MVA-VLPTMvaccine platformand expertise to develop vaccine candidates using genetic sequences from SARS-CoV-2, the virus responsible for the ongoing COVID-19 outbreak.

Key Points: 
  • GeoVax is using itsGV-MVA-VLPTMvaccine platformand expertise to develop vaccine candidates using genetic sequences from SARS-CoV-2, the virus responsible for the ongoing COVID-19 outbreak.
  • GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novelproprietaryvaccine platform (GV-MVA-VLPTM).
  • Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act.
  • GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so.

Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine

Monday, March 30, 2020 - 12:00pm

Altimmune has significant experience in the development of intranasal vaccines for respiratory pathogens, including NasoVAX, a seasonal and pandemic influenza vaccine candidate, and NasoShield, a vaccine candidate for inhalation anthrax.

Key Points: 
  • Altimmune has significant experience in the development of intranasal vaccines for respiratory pathogens, including NasoVAX, a seasonal and pandemic influenza vaccine candidate, and NasoShield, a vaccine candidate for inhalation anthrax.
  • NasoShield is being developed under a $133.7 million contract with Biomedical Advanced Research and Development Authority (BARDA).
  • UAB has an impressive track record of cutting-edge research in virology and immunology, as well as in the clinical development of vaccines.
  • AdCOVID is a single-dose, intranasal vaccine candidate designed to protect against COVID-19, the disease caused by the SARS-CoV-2 virus.

5 Questions with a Virus Expert on COVID-19

Friday, March 27, 2020 - 5:25pm

Being a new virus that has never circulated in humans before means that vaccine research essentially started when the virus was identified in December 2019.

Key Points: 
  • Being a new virus that has never circulated in humans before means that vaccine research essentially started when the virus was identified in December 2019.
  • Simply put, until it was identified, there was no virus to design a vaccine against.
  • Also, the original SARS-CoV emerged in 2003, and generating a vaccine to that virus has proven to be challenging.
  • These responses include inflammation, inducing cell death to destroy both the cell and the virus, and activating antiviral proteins such as interferon.

Global Influenza Vaccines Market Assessment, 2013-2027 with Analysis of Key & Emerging Players: Sanofi Pasteur, GSK, Seqirus, AstraZeneca, Novavax, BiondVax Pharmaceuticals, Moderna, and More

Friday, March 27, 2020 - 11:00am

This 260-page report, Worldwide Influenza Vaccines Market Size, Share, Analysis, Growth, Trends, and Forecast to 2027 is based on comprehensive research of the worldwide influenza vaccines market.

Key Points: 
  • This 260-page report, Worldwide Influenza Vaccines Market Size, Share, Analysis, Growth, Trends, and Forecast to 2027 is based on comprehensive research of the worldwide influenza vaccines market.
  • The report offers the most up-to-date industry data on the actual market situation and future outlook for the worldwide influenza vaccines market.
  • The report contains a deep analysis of the worldwide influenza vaccines market with size in terms of both value and volume.
  • 4.1 Number of Persons Vaccinated with Influenza Vaccines Share, 2013 - 2027(%)
    4.2 Influenza Vaccines Market Share, 2013 - 2027(%)